Previous reports have shown that FGF2 counteracts TGF‐β‐induced mesenchymal transition of various types of endothelial cells including primary cultured mouse endothelial cells from heart and liver (Chen et al., 2012, 2014, 2015), HUVECs (Correia et al., 2016), and TECs isolated from tumor tissues formed in the transgenic mouse models of various types of cancer (Xiao et al., 2015). Here, FGF2 is linked to cancer.